IMMUNOTHERAPEUTIC TUMOR TREATMENT METHOD
Provided herein are methods and compositions for treating a subject having cancer by administering to the subject a cancer vaccine accompanied by administration of a long acting IL-2Rαβ-biased agonist.
1 . A method of administration, the method comprising administering to a subject having cancer an IL-2Rβ-activating amount of a long acting IL-2Rβ-biased agonist and a cancer vaccine, wherein the long-acting IL-2Rβ-biased agonist is administered at a dose that is less than about 0.7 mg/kg.
2 . A method of enhancing the therapeutic effectiveness of a cancer vaccine, comprising administering to a subject having cancer a cancer vaccine and an IL-2Rβ-activating amount of a long-acting IL-2Rβ-biased agonist, wherein the long-acting IL-2Rβ-biased agonist is administered at a dose that is less than 0.7 mg/kg, and the administering of the long-acting IL-2Rβ-biased agonist is effective to improve the subject's response to the vaccine.
3 . A method of treating cancer in a subject, comprising administering to the subject an IL-2Rβ-activating amount of a long-acting IL-2Rβ-biased agonist and a cancer vaccine in an amount effective to treat cancer, wherein the long-acting IL-2Rβ-biased agonist is administered at a dose that is less than about 0.7 mg/kg, and when evaluated in a mouse model of the cancer using equivalent amounts of the long acting IL-2Rβ-biased agonist and the vaccine, is effective to prolong survival over administration of the cancer vaccine and a non-long acting version of the IL-2 agonist by at least 15 days based upon the time delay between 50% maximum tumor growth for each of the foregoing treatments.
4 . A method of inhibiting accumulation of regulatory T cells (Tregs) in a subject undergoing treatment for cancer, comprising administering to the subject an IL-2Rβ-activating amount of a long acting IL-2Rβ-biased agonist and a cancer vaccine in an amount effective to treat cancer, where when evaluated in a mouse model of cancer using equivalent amounts of the long acting IL-2Rβ-biased agonist and the vaccine, is effective to inhibit accumulation of regulatory T cells selected from the group consisting of CD4+ Tregs, CD25+ Tregs, and FoxP3+ Tregs in the tumor by an amount that is enhanced over that observed upon administration of a non-long acting IL-2Rβ-biased agonist and the vaccine.
5 . The method of claim 1 , wherein the vaccine is administered to the subject separately from the long acting IL-2Rβ-biased agonist.
6 . The method of claim 5 , wherein the vaccine is administered to the subject prior to administering the long acting IL-2Rβ-biased agonist.
7 . The method of claim 1 , wherein the vaccine and the long acting IL-2Rβ-biased agonist are both administered on day 1 of treatment.
8 . The method of claim 1 , wherein the vaccine is administered on day 1 of treatment and the long acting IL-2Rβ-biased agonist is administered at any one of days 1 to 4 of treatment.
9 . The method of claim 1 , wherein the subject is a human.
10 . The method of claim 1 , wherein the cancer is a solid cancer.
11 . The method of claim 10 , wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, colon cancer, prostate cancer, bone cancer, colorectal cancer, gastric cancer, lymphoma, malignant melanoma, liver cancer, small cell lung cancer, non-small cell lung cancer, pancreatic cancer, thyroid cancers, kidney cancer, cancer of the bile duct, brain cancer, cervical cancer, maxillary sinus cancer, bladder cancer, esophageal cancer, Hodgkin's disease and adrenocortical cancer.
12 . The method of claim 11 , wherein the cancer is a malignant melanoma.
13 . The method of claim 1 , wherein the long acting IL-2Rβ-biased agonist is administered at a dose in a range of less than 0.7 mg/kg to about 0.2 mg/kg.
14 . The method of claim 10 , wherein the administering is effective to result in a reduction in solid tumor size of at least 25% when evaluated after 1 cycle of treatment.
15 . The method of claim 1 , wherein the long acting IL-2Rβ-biased agonist comprises aldesleukin releasably covalently attached to polyethylene glycol.
16 . The method of claim 15 , wherein the long acting IL-2Rβ-biased agonist comprises aldesleukin releasably covalently attached to an average of 6 polyethylene glycol polymers.
17 . The method of claim 1 , wherein the vaccine is selected from an antigen vaccine, a whole cell vaccine, a dendritic cell vaccine, and a DNA vaccine.
18 . The method of claim 17 , wherein the vaccine is an allogenic vaccine.
19 . The method of claim 17 , wherein the vaccine is an autologous vaccine.
20 . The method of claim 17 , wherein the vaccine is an antigen vaccine.
21 . The method of claim 20 , wherein the antigen vaccine comprises a tumor-specific antigen.
22 . The method of claim 21 , wherein the tumor-specific antigen is selected from a cancer-testis antigen, a differentiation antigen, and a widely-occurring over-expressed tumor associated antigen.
23 . The method of claim 20 , wherein the vaccine comprises a neoantigen.
24 . The method of claim 1 , wherein the vaccine is administered in the form of a composition comprising one or more adjuvants.
25 . A kit comprising an IL-2Rβ-activating amount of a long acting IL-2Rβ-biased agonist and a vaccine, accompanied by instructions for use in treating a subject having cancer.
26 . (canceled)
27 . (canceled)
28 . (canceled)
29 . (canceled)
30 . The kit of claim 25 , wherein both the long-acting IL-2Rβ-biased agonist and the vaccine are in solid form.
31 . (canceled)
32 . (canceled)
33 . The kit of claim 25 , wherein both the long acting IL-2Rβ-biased agonist and the vaccine are in a solid form suitable for reconstitution in an aqueous diluent.